BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $15.00 Price Target at JMP Securities

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective increased by JMP Securities from $14.00 to $15.00 in a research report sent to investors on Tuesday, Benzinga reports. JMP Securities currently has a market outperform rating on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on the company. Needham & Company LLC reiterated a buy rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. HC Wainwright restated a buy rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average target price of $14.00.

BioCryst Pharmaceuticals Stock Down 0.2 %

Shares of BCRX opened at $5.26 on Tuesday. The business’s 50-day moving average price is $4.90 and its 200-day moving average price is $5.45. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $8.96. The stock has a market cap of $1.09 billion, a PE ratio of -4.46 and a beta of 1.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $92.80 million for the quarter, compared to the consensus estimate of $85.62 million. During the same period last year, the company posted ($0.28) EPS. The business’s revenue was up 34.9% on a year-over-year basis. Analysts expect that BioCryst Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of BCRX. China Universal Asset Management Co. Ltd. lifted its position in BioCryst Pharmaceuticals by 96.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after buying an additional 2,388 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of BioCryst Pharmaceuticals by 4.9% in the 3rd quarter. Teacher Retirement System of Texas now owns 53,640 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 2,519 shares during the last quarter. Fifth Third Bancorp boosted its stake in shares of BioCryst Pharmaceuticals by 17,500.0% in the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,500 shares in the last quarter. Teza Capital Management LLC grew its holdings in shares of BioCryst Pharmaceuticals by 12.8% during the 3rd quarter. Teza Capital Management LLC now owns 36,904 shares of the biotechnology company’s stock valued at $261,000 after purchasing an additional 4,180 shares during the last quarter. Finally, Great Valley Advisor Group Inc. raised its position in BioCryst Pharmaceuticals by 34.7% in the 3rd quarter. Great Valley Advisor Group Inc. now owns 16,300 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 4,200 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.